TickerFacts.

Valion Bio, Inc. (VBIO): Cash & Equivalents

Annual figures by period end, from SEC filings.

$12.64M
As of 2025-12-31
$2.11M
As of 2026-06-30
+53.2%
3-year compound annual growth
$12.97M2021-12-31: $12.97M2022-12-31: $3.52M2023-12-31: $3.40M2024-12-31: $2.00M2025-12-31: $12.64M$12.64M
2021-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$12.64M+531.6%2026-03-30, Balance as of period end
2024-12-31$2.00M-41.0%2026-03-30, Balance as of period end
2023-12-31$3.40M-3.5%2025-03-21, Balance as of period end
2022-12-31$3.52M-72.9%2024-03-25, Balance as of period end
2021-12-31$12.97Mn/a2023-03-31, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Valion Bio, Inc. (VBIO)2025-12-31$12.64M+531.6%
Nuvectis Pharma, Inc. (NVCT)2025-12-31$31.63M+70.7%
Equillium, Inc. (EQ)2025-12-31$30.28M+67.4%
Tvardi Therapeutics, Inc. (TVRD)2025-12-31$20.73M-34.4%
China Pharma Holdings, Inc. (CPHI)2025-12-31$345.1K-44.9%
Dare Bioscience, Inc. (DARE)2025-12-31$24.71M+57.4%
PDS Biotechnology Corp (PDSB)2025-12-31$26.71M-35.9%
Yarrow Bioscience, Inc. (YARW)2025-12-31$24.03M+20.6%
Sol-Gel Technologies Ltd. (SLGL)2025-12-31$11.03M-43.4%

Compare VBIO, NVCT, EQ, TVRD side by side · Screen every company in Pharmaceutical Preparations ↗